MFDS approves emergency use of Pfizer’s oral COVID-19 drug
By Lee, Tak-Sun | translator Alice Kang
21.12.27 13:10:00
가나다라
0
Used on Mild-to-moderate COVID-19 patients aged 12 or older at high risk of progressing to severe disease
Risk of hospitalization and death reduced by 88% when administered within 5 days after onset of symptoms or diagnosis
Will be administered to patients treated from home with doctor’s prescriptions… supplied by pharmacies
Authorities plan to use the drug to treat adults and pediatric patients over the age of 12 with mild-to-moderate COVID-19 at high risk of progressing to severe disease. Pharmacies will be supplying the pills for patients treated from their homes.
On the 27th, the Ministry of Food and Drug Safety announced that it had authorized the emergency use of ‘Paxlovid,’ an oral COVID-19 treatment developed by the US company Pfizer.
The decision was made after a comprehensive deliberation into the need to introduce oral treatment options that patients can self—administer amid
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)